Trial results

Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility

NCT05952882 on ClinicalTrials.gov · last registry update 2023-10-23

A small phase 3 — 188 participants, against a typical 424. Its estimated completion date, 31 December 2025, has passed with no update to the record. Primary outcome, as filed: Absolute Body Weight (BW). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

UNKNOWN

Phase

P3

Drug

liraglutide

Victoza, Xultophy, Saxenda

Sponsor

Mỹ Đức Hospital

Sponsor type

Other

Enrollment

188

Started

2023-11-01

Primary completion

2025-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Absolute Body Weight (BW)

Conditions studied

Polycystic Ovary Syndrome · Obesity · Infertility, Female

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.